Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: cross-reactivity does not depend on molecular weight. Commentary.


weeks 6 and 12 of efalizumab treatment. It was originally described in patients who experience a continuous worsening of psoriasis from beginning of therapy. Very recently another group of patients has been identified who may experience a generalized exacerbation, namely long-term responders in the context of infections. Here we show that this adverse event… (More)
DOI: 10.1111/j.1365-2133.2008.08453.x